ライフサイエンスコーパス: exertional dyspnea

1 She has symptoms of fatigue, achiness, and exertional dyspnea.

2 to our hospital after developing progressive exertional dyspnea.

3 manifests with symptoms such as fatigue and exertional dyspnea.

4 tical activation were potentially related to exertional dyspnea.

5 30 individuals reported relevant persistent exertional dyspnea.

6 nt in 74% of patients, with symptoms such as exertional dyspnea (14%) and chronic cough (9%).

7 agm muscle weakness and its association with exertional dyspnea 2 years after hospitalization for COV

8 Most commonly reported symptoms were exertional dyspnea (78%) and fatigue (73%).

9 I] = 0.9-6.6%), a 1.6-fold increased odds of exertional dyspnea (95% CI = 1.3-1.9), a 1.5-fold increa

10 d persistent CCS symptoms such as fatigue or exertional dyspnea after convalescence and healthy contr

11 Affected patients often experience severe exertional dyspnea and debilitating fatigue, as well as

12 Patients with exertional dyspnea and diastolic dysfunction on echocard

13 previously healthy soldiers with unexplained exertional dyspnea and diminished exercise tolerance aft

14 t children with asthma may falsely attribute exertional dyspnea and esophageal reflux to asthma, lead

15 -induced laryngeal obstruction (EILO) causes exertional dyspnea and is important for its effect on qu

16 ] age 70 +/- 12 years; 21 women, 9 men) with exertional dyspnea and negative exercise test results, a

17 The authors studied individuals with chronic exertional dyspnea and preserved ejection fraction who u

18 to severe AS, such as exercise intolerance, exertional dyspnea, and syncope, are associated with a 1

19 HF symptoms, especially exertional dyspnea, are common in ARVC/D; yet, classic l

20 ient selection, including drug treatment for exertional dyspnea (beta-blockers, verapamil, disopyrami

21 s with moderate to severe heart failure that exertional dyspnea can be alleviated by improving muscle

22 pacemakers were implanted in 9 patients with exertional dyspnea caused by HHCO.

23 Exertional dyspnea, chest pain, palpitations, and ankle

24 D-19-related persisting symptoms (resting or exertional dyspnea, cough, fatigue) underwent same-day E

25 gm muscle weakness might underlie persistent exertional dyspnea, despite normal lung and cardiac func

26 Exertional dyspnea disproportionate to pulmonary functio

27 ssive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death.

28 iaphragm and inspiratory muscle weakness and exertional dyspnea in individuals with long COVID.

29 dentify a potential treatment for persisting exertional dyspnea in long COVID and provide a possible

30 Exertional dyspnea is a frequent limiting symptom in pat

31 Amelioration of exertional dyspnea is achieved by other mechanisms, such

32 After heart transplantation, exertional dyspnea is markedly diminished.

33 The most common clinical presentation was exertional dyspnea (n=17; 65%), whereas 8 (31%) patients

34 e examined consecutive patients with chronic exertional dyspnea (New York Heart Association class II

35 rial, 150 subjects (age 67 +/- 9 years) with exertional dyspnea (New York Heart Association functiona

36 ars of age) with stage C heart failure (HF) (exertional dyspnea, New York Heart Association functiona

37 Exertional dyspnea or chest pain, prior limitation from

38 Thirty additional participants without exertional dyspnea served as controls.

39 th PRISm, lower exercise capacity and higher exertional dyspnea than healthy controls were mainly exp

40 with heart failure are frequently limited by exertional dyspnea that may be due to the increased work

41 ith persistent diaphragm muscle weakness and exertional dyspnea were randomized to 6 weeks of IMT or